Search Result

Pathways Recommended:	PI3K/Akt/mTOR

Results for "

PI3K kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PI3K (47) Akt (2) Amino Acid Derivatives (1) Antibiotic (1) Apoptosis (9) ATM/ATR (5) Autophagy (5) Casein Kinase (6) CDK (3) Cytochrome P450 (1) DNA-PK (2) IKK (1) Integrin (1) mTOR (15) NF-κB (1) Organoid (1) PKC (1) Polo-like Kinase (PLK) (2) RET (1) ROR (1)
By Research Areas:	Cancer (53) Infection (1) Inflammation/Immunology (6)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Targets Recommended: PI3K

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147419

Vulolisib	PI3K	Cancer
Vulolisib is a potent and orally active phosphatidylinositol 3-kinase (PI3K) inhibitor, with IC₅₀ values of 0.2 nM, 168 nM, 90 nM and 49 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively. Antiproliferative and antineoplastic activity .

HY-16585

VS-5584 5 Publications Verification SB2343	PI3K mTOR	Cancer
VS-5584 is a *pan-PI3K/mTOR* kinase inhibitor with IC₅₀s of 16 nM, 68 nM, 42 nM, 25 nM, and 37 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. VS-5584 simultaneously blocks mTORC2 as well as mTORC1.

HY-143275

HL-8	PI3K	Cancer
HL-8 is a PROTAC molecule targeting PI3K kinase. HL-8 has a significant and complete degradation effect on PI3K kinase at a concentration of 10 μM within 8 h. HL-8 has the potential for the research of cancer diseases .

HY-142677

PI3K-IN-27	PI3K	Inflammation/Immunology Cancer
PI3K-IN-27 is a potent inhibitor of PI3K. PI3K belongs to a large family of lipid signaling kinase that plays key role in cellular process including cell growth, differentiation, migration and apoptosis. PI3K-IN-27 has the potential for the research of hyper-proliferative diseases like cancer and inflammation, or immune and autoimmune diseases (extracted from patent WO2021233227A1, compound 1) .

HY-139880

PI3Kγ inhibitor 5

PI3K Cancer

PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ (PI3Kγ) with an IC₅₀ value of 34 nM.

PI3Kγ inhibitor 5	PI3K	Cancer
PI3Kγ inhibitor 5 is an inhibitor of phosphoinositide 3-kinase γ *(PI3Kγ)* with an IC₅₀ value of 34 nM.

HY-155975

PI3Kδ-IN-14	PI3K	Inflammation/Immunology
PI3Kδ-IN-14 (Compound (S)-29) is a selective PI3Kδ inhibitor (IC₅₀: 0.8 nM, K_d: 84.8 nM). PI3Kδ-IN-14 binds to the ATP-binding site of the kinase domain of PI3Kδ. PI3Kδ-IN-14 has anti-inflammatory activity by inhibiting the PI3K/AKT pathway. PI3Kδ-IN-14 ameliorates acute lung injury (ALI) .

HY-10620

PI3K-IN-22	PI3K mTOR	Cancer
PI3K-IN-22 is a PI3Kα/mTOR dual kinase inhibitor. PI3K-IN-22 has IC₅₀s of 0.9, 0.6 nM for PI3Kα and mTOR, respectively. PI3K-IN-22 can be used for the research of cancer .

HY-123849

SN32976	PI3K mTOR	Cancer
SN32976 is a potent and selective class I *PI3K* and mTOR inhibitor with IC₅₀s of 15.1 nM, 461 nM, 110 nM, 134 nM and 194 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ and mTOR, respectively. SN32976 shows high selectivity among other 442 kinases. SN32976 shows anticancer effects .

HY-10811

GNE-493 2 Publications Verification	PI3K mTOR	Cancer
GNE-493 is a potent, selective, and orally available dual *pan-PI3-kinase/mTOR* inhibitor with IC₅₀s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR.

HY-141690A

PI3K-IN-19 hydrochloride

PI3K Cancer

PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2017153220, step 5 .

PI3K-IN-19 hydrochloride	PI3K	Cancer
PI3K-IN-19 hydrochloride is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2017153220, step 5 .

HY-153120A

PI3K/mTOR Inhibitor-13 sodium	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 sodium is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 sodium has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-153120

PI3K/mTOR Inhibitor-13	PI3K mTOR	Cancer
PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) .

HY-160283

PI3K-IN-50

PI3K Cancer

PI3K-IN-50 is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2023239710A1, example 35 .

PI3K-IN-50	PI3K	Cancer
PI3K-IN-50 is a phosphotidylinositol-3-kinase (PI3K) inhibitor extracted from patent WO2023239710A1, example 35 .

HY-163360

PI3Kα-IN-19	PI3K	Cancer
PI3Kα-IN-19 (Compound 1) is a PI3Kα inhibitor with a targeted binding site at the p110α catalytic subunit. PI3Kα is one of the most common dysregulated kinases used in cancer research .

HY-101115

PI3K-IN-6	PI3K	Cancer
PI3K-IN-6 (compound 20a) is an oral active and highly selective *phosphoinositide 3-kinase* (PI3K) β/δ inhibitor, with IC₅₀** values of 7.8 nM/5.3 nM for PI3K β/δ, respectively. PI3K-IN-6 (compound 20a) has potential top treat phosphatase and tensin homolog (PTEN) feficient tumors .

HY-15346

Copanlisib 20+ Cited Publications BAY 80-6946	PI3K Apoptosis	Cancer
Copanlisib (BAY 80-6946) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib has superior antitumor activity .

HY-15346A

Copanlisib dihydrochloride 20+ Cited Publications BAY 80-6946 dihydrochloride	PI3K Apoptosis	Cancer
Copanlisib dihydrochloride (BAY 80-6946 dihydrochloride) is a potent, selective and ATP-competitive pan-class I *PI3K* inhibitor, with IC₅₀s of 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3Kα, PI3Kδ, PI3Kβ and PI3Kγ, respectively. Copanlisib dihydrochloride has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR. Copanlisib dihydrochloride has superior antitumor activity .

HY-13246

Apitolisib 10+ Cited Publications GDC-0980; GNE 390; RG 7422	PI3K mTOR Apoptosis	Cancer
Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I *PI3* kinase and mTOR kinase (TORC1/2) inhibitor with IC₅₀s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a K_i of 17 nM for mTOR.

HY-100398

PF-04979064 2 Publications Verification	PI3K mTOR	Cancer
PF-04979064 is a potent and selective *PI3K/mTOR* dual kinase inhibitor with K_is of 0.13 nM and 1.42 nM for PI3Kα and mTOR, respectively.

HY-131972

PF-06843195	PI3K	Cancer
PF-06843195 is a highly selective PI3Kα inhibitor with an IC₅₀ of 18 nM in Rat1 fibroblasts. The K_is of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K/mTOR signaling pathway and durable antitumor efficacy .

HY-10108

LY294002 Maximum Cited Publications 686 Publications Verification	PI3K Casein Kinase DNA-PK Apoptosis Autophagy	Infection Cancer
LY294002 is a broad-spectrum inhibitor of *PI3K* with IC₅₀s of 0.5, 0.57, and 0.97 μM for PI3Kα, PI3Kδ and PI3Kβ, respectively . LY294002 also inhibits CK2 with an IC₅₀ of 98 nM . LY294002 is a competitive DNA-PK inhibitor that binds reversibly to the kinase domain of DNA-PK with an IC₅₀ of 1.4 μM. LY294002 is an apoptosis activator .

HY-11002

CP-466722 4 Publications Verification	ATM/ATR	Cancer
CP-466722 is a rapidly reversible inhibitor of ATM, with an IC₅₀ of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members.

HY-12948

AMG319

PI3K Cancer

AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC₅₀ of 18 nM.

AMG319	PI3K	Cancer
AMG319 is a potent and selective PI3Kδ kinase inhibitor with IC₅₀ of 18 nM.

HY-15174

Dactolisib Tosylate 45+ Cited Publications BEZ235 Tosylate; NVP-BEZ 235 Tosylate	PI3K mTOR Autophagy	Cancer
Dactolisib Tosylate (BEZ235 Tosylate) is a dual *PI3K* and mTOR kinase inhibitor with IC₅₀ values of 4, 75, 7, 5 nM for PI3Kα, β, γ, δ, respectively. Dactolisib Tosylate (BEZ235 Tosylate) inhibits mTORC1 and mTORC2.

HY-131910

IHMT-PI3Kδ-372	PI3K Cytochrome P450	Inflammation/Immunology
IHMT-PI3Kδ-372 is a potent and selective PI3Kδ inhibitor with an IC₅₀ of 14 nM. IHMT-PI3Kδ-372 shows high selectivity over other class I PI3Ks (56∼83 fold) and other protein kinases. IHMT-PI3Kδ-372 can be uesd for chronic obstructive pulmonary disease (COPD) research .

HY-156406

PITCOIN4	PI3K	Inflammation/Immunology
PITCOIN4 is a highly selective Class II Alpha *PI3K-C2α* inhibitor. PITCOIN4 shows nanomolar inhibition of PI3K-C2α and >100-fold selectivity in a general kinase panel .

HY-109029

Dezapelisib INCB040093	PI3K	Cancer
Dezapelisib (NCB040093) is a potent inhibitor of phosphatidylinositol 3-kinase δ (PI3Kδ). Dezapelisib is a promising research strategy for select R/R B-cell lymphomas .

HY-161366

OMS14	PI3K	Cancer
OMS14 is exhibits inhibitory activity for phosphoinositide 3-kinase γ (PI3Kγ) and PIK3CD/PIK3R1, which inhibits 19% PI3Kγ and 65% PIK3CD/PIK3R1 activity at 100 μM. OMS14 exhibits anticancer efficacy in various cancer cells .

HY-100716

Eganelisib 10+ Cited Publications IPI-549	PI3K	Cancer
Eganelisib (IPI549) is a potent and selective PI3Kγ inhibitor with an IC₅₀ of 16 nM. Eganelisib shows >100-fold selectivity over other lipid and protein kinases .

HY-135827A

Roginolisib hemifumarate MSC2360844 hemifumarate; IOA-244 hemifumarate	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC₅₀ of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases .

HY-135827

Roginolisib MSC2360844; IOA-244	PI3K	Inflammation/Immunology Cancer
Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC₅₀ of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases .

HY-114457

Phosphatidylinositol 4,5-bisphosphate L-alpha-Phosphatidylinositol-4,5-bisphosphate	PI3K	Others
Phosphatidylinositol 4,5-bisphosphate (L-alpha-Phosphatidylinositol-4,5-bisphosphate), a phospholipid component of cell membranes, is a substrate for phospholipase C (PLC) and phosphoinositide 3-kinase (PI3K) and as a primary messenger .

HY-108606

PI-828 1 Publications Verification	PI3K Casein Kinase	Cancer
PI-828 is a dual *PI3K* and *casein kinase* 2 (CK2) inhibitor with IC₅₀s of 173 nM, 149 nM, and 1127 nM for p110α, CK2, and CK2α2** in lipid kinase assay, respectively .

HY-109198

Zandelisib ME-401; PWT-143	PI3K	Cancer
Zandelisib (ME-401) is a phosphatidylinositol 3-kinase (PI3K) inhibitor extracted from patent WO2019183226 A1, Compound Example 1. Zandelisib selectively inhibits p110δ with an IC₅₀ of 3.5 nM. Zandelisib functions as an antineoplastic .

HY-144686

ATM Inhibitor-3	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-3 (compound 34) is a potent and selective ATM inhibitor, with an IC₅₀ of 0.71 nM. ATM Inhibitor-3 shows inhibition of *PI3K* kinases family. ATM Inhibitor-3 exhibits favorable metabolic stability .

HY-147567

ATR-IN-15	ATM/ATR DNA-PK PI3K	Cancer
ATR-IN-15 (compound 1) is an orally active and potent ATR kinase inhibitor, with an IC₅₀ of 8 nM. ATR-IN-15 also inhibits human colon tumor cells LoVo, DNA-PK and *PI3K, with IC₅₀* values of 47, 663 and 5131 nM, respectively .

HY-N5072

Desmethylglycitein 4',6,7-Trihydroxyisoflavone	CDK PI3K PKC	Cancer
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity . Desmethylglycitein is a direct inhibitor of protein kinase C (PKC)α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 (MMP1) . Desmethylglycitein binds to *PI3K* in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes .

HY-10197

Wortmannin 100+ Cited Publications SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible *PI3K* inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits *Polo-like kinase* 1 (PlK1) and Plk3 with IC₅₀**s of 5.8 and 48 nM, respectively .

HY-139609

Camonsertib RP-3500; ATR inhibitor 4	ATM/ATR mTOR	Cancer
Camonsertib (RP-3500) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC₅₀ of 1.00 nM in biochemical assays. Camonsertib shows 30-fold selectivity for ATR over mTOR (IC₅₀=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. Camonsertib has potent antitumor activity .

HY-144687

ATM Inhibitor-4	ATM/ATR PI3K mTOR	Cancer
ATM Inhibitor-4 (compound 39) is a potent and selective ATM inhibitor, with an IC₅₀ of 0.32 nM. ATM Inhibitor-4 shows stronger inhibition of *PI3K* kinases family. ATM Inhibitor-4 shows a full inhibition of mTOR at 1 μM. ATM Inhibitor-4 exhibits favorable metabolic stability .

HY-12279

Umbralisib 3 Publications Verification TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .

HY-12279C

Umbralisib hydrochloride 3 Publications Verification TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .

HY-12279A

Umbralisib tosylate TGR-1202 tosylate; RP5264 tosylate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) tosylate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib tosylate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib tosylate can be used for haematological malignancies reseach .

HY-116035

Nimbolide 1 Publications Verification	NF-κB CDK Apoptosis	Cancer
Nimbolide is a triterpene compound that can be isolated from neem (Azadirachta indica), possesses anticancer and antiproliferative activity. Nimbolide induces tumor cell apoptosis by inhibiting NF-κB and CDK4/CDK6 kinase. Nimbolide suppresses the Wnt, PI3K-Akt, MAPK and JAK-STAT signaling pathways .

HY-12279B

Umbralisib sulfate TGR-1202 sulfate; RP-5264 sulfate	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) sulfate is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib sulfate exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib sulfate can be used for haematological malignancies reseach .

HY-W005308

N-BOC-DL-serine methyl ester	Amino Acid Derivatives	Cancer
N-BOC-DL-serine methyl ester is a Serine derivative. N-BOC-DL-serine methyl ester is used for the synthesis of α,β-dehydro-α-amino acid. N-BOC-DL-serine methyl ester is also used for the synthesis of anti-cancer agent, such as quinazolinone derivative that inhibits PI3K activity, and tricyclic pyrolopyranopyridines that inhibits protein kinase activity .

HY-144059

AKT-IN-9	Akt	Cancer
AKT-IN-9 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-9 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 1) .

HY-144060

AKT-IN-10	Akt	Cancer
AKT-IN-10 is a potent inhibitor of AKT. Protein kinase B (PKB, also known as AKT) is central to PI3K/AKT/mTOR signaling in cells, and its function is important for cell growth, survival, differentiation and metabolism. AKT-IN-10 has the potential for the research of breast and prostate cancer (extracted from patent WO2021185238A1, compound 4) .

HY-12037

Rigosertib sodium 5 Publications Verification ON-01910 sodium	Polo-like Kinase (PLK) PI3K Apoptosis	Cancer
Rigosertib sodium (ON-01910 sodium) is a multi-kinase inhibitor and a selective anti-cancer agent, which induces apoptosis by inhibition the *PI3K/Akt* pathway, promotes the phosphorylation of histone H2AX and induces G2/M arrest in cell cycle . Rigosertib sodium is a selective and non-ATP-competitive inhibitor of PLK1 with an IC₅₀ of 9 nM .

HY-12895

SKI V 1 Publications Verification
SKI V is a noncompetitive and potent non-lipid *sphingosine kinase* (SPHK; SK) inhibitor with an IC₅₀ of 2 μM for GST-hSK. SKI V potently inhibits PI3K with an IC₅₀ of 6 μM for hPI3k. SKI V decreases formation of the mitogenic second messenger sphingosine-1-phosphate (S1P). SKI V induces apoptosis** and has antitumor activity .

Cat. No.	Product Name

HY-L009

Kinase Inhibitor Library

3137 compounds

Kinase is an enzyme that adds phosphate groups to other molecules. This process is known as phosphorylation. Protein phosphorylation is a key aspect in the regulation of a large number of cellular processes including cellular division, metabolism, signal transduction, and so on. There are over 500 kinases encoded by the human genome and it has been estimated that kinases regulate approximately 50% of cellular functions. Kinases are a large group of drug targets in drug discovery. Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders.

Kinase inhibitor library designed by MCE contains 3137 kinase inhibitors and regulators mainly targeting protein kinases (VEGFR, EGFR, BTK, CDK, Akt, etc.), lipid kinases (PI3K, PI4K, SK, etc.) and carbohydrate kinases (Hexokinase), and is a useful tool for kinase drug discovery and related research.

HY-L015

PI3K/Akt/mTOR Compound Library

568 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 568 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Species:	Human (2)
Tag:	His (2) GST (2)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701752

	PK3C3 Protein, Human (Sf9, His, GST) PIK3C3; Phosphatidylinositol 3-kinase catalytic subunit type 3; PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34	Human	Sf9 insect cells
	The PI3KC3 protein is the catalytic subunit of the PI3K complex and mediates the formation of phosphatidylinositol 3-phosphate. PI3KC3-C1 initiates autophagosomes, whereas PI3KC3-C2 promotes autophagosome maturation and endocytosis. PK3C3 Protein, Human (Sf9, His, GST) is the recombinant human-derived PK3C3 protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of PK3C3 Protein, Human (Sf9, His, GST) is 886 a.a., .

HY-P701744

	PIK3R3 Protein, Human (Sf9, His, GST) PIK3R3; Phosphatidylinositol 3-kinase regulatory subunit gamma; PI3-kinase regulatory subunit gamma; PI3K regulatory subunit gamma; PtdIns-3-kinase regulatory subunit gamma; Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; PI3-kinase subunit p55-gamma; PtdIns-3-kinase regulatory subunit p55-gamma; p55PIK	Human	Sf9 insect cells
	PIK3R3 protein, through its SH2 domain, interacts with phosphorylated protein-tyrosine kinases, crucially regulating their kinase activity. During insulin stimulation, PIK3R3 binds to IRS-1. Operating as a heterodimer with a p110 catalytic subunit, it interacts with AXL, expanding its functional network. PIK3R3 Protein, Human (Sf9, His, GST) is the recombinant human-derived PIK3R3 protein, expressed by Sf9 insect cells , with N-8*His, N-GST labeled tag. The total length of PIK3R3 Protein, Human (Sf9, His, GST) is 460 a.a., .

Cat. No.	Product Name	Application	Reactivity

HY-P80866

PI3 Kinase p55 gamma Antibody GRB1; P85A; PI3-kinase p85-alpha subunit; PI3K; PI3K p85-alpha; P55G; PI3-kinase p85-gamma subunit; PI3K p85-gamma	WB, IHC-P, ICC/IF	Human, Mouse, Rat
PI3 Kinase p55 gamma Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 54 kDa, targeting to PI3 Kinase p55 gamma. It can be used for WB,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse, Rat.

HY-P80865

PI3 Kinase p110 gamma Antibody (YA690) 1 Publications Verification PI3K; PIK3; PI3CG; PI3Kgamma; p110gamma; p120-PI3K	WB	Human
PI3 Kinase p110 gamma Antibody (YA690) is a non-conjugated and Mouse origined monoclonal antibody about 126 kDa, targeting to PI3 Kinase p110 gamma (2D10). It can be used for WB assays with tag free, in the background of Human.

HY-P80867

PI3 Kinase p85 alpha Antibody (YA689) PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-P	Human, Mouse, Rat
PI3 Kinase p85 alpha Antibody (YA689) is a non-conjugated and Mouse origined monoclonal antibody about 84 kDa, targeting to PI3 Kinase p85 alpha (1C8). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

HY-P80846

Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody 1 Publications Verification PIK3R1; GRB1; Phosphatidylinositol 3-kinase regulatory subunit alpha; PI3-kinase regulatory subunit alpha; PI3K regulatory subunit alpha; PtdIns-3-kinase regulatory subunit alpha; Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; PI3-kinase s	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat, Monkey
Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 84 kDa, targeting to Phospho-PI3 Kinase p85/p55 (Tyr467/Tyr199). It can be used for WB,IHC-F,IHC-P,ICC/IF,ELISA assays with tag free, in the background of Human, Mouse, Rat, Monkey.

HY-P81229

PI3 Kinase p110 beta Antibody PI3-kinase p110 subunit beta; p110 BETA; p110Beta; PI3K beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; PIk3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB; ELISA; IHC-P; IHC-F; Flow-Cyt; ICC; IF	Human, Mouse, Rat(predicted: Dog, Cow, Horse, Rabbit)
PI3 Kinase p110 beta Antibody is an unconjugated, approximately 123 kDa, rabbit-derived, anti-PI3 Kinase p110 beta polyclonal antibody. PI3 Kinase p110 beta Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, ICC, IF expriments in human, mouse, rat, and predicted: dog, cow, horse, rabbit background without labeling.

HY-P83044

PIK3C3 Antibody (YA2789) Phosphatidylinositol 3-kinase catalytic subunit type 3 (EC:2.7.1.137); PI3-kinase type 3; PI3K type 3; PtdIns-3-kinase type 3; Phosphatidylinositol 3-kinase p100 subunit; Phosphoinositide-3-kinase class 3; hVps34; VPS34 antibodyPIK3C3；	WB, IHC-P	Human, Mouse, Rat

HY-P81211

phospho-PI3 Kinase p110 beta (Ser1070) Antibody PI3-kinase p110 subunit beta; p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; PIk3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform.	WB; ELISA; IHC-P; IHC-F; IF	Human, Mouse, Rat(predicted: Chicken, Dog, Pig, Cow, Horse, Guinea Pig)
phospho-PI3 Kinase p110 beta (Ser1070) Antibody is an unconjugated, approximately 110-123 kDa, rabbit-derived, anti-phospho-PI3 Kinase p110 beta (Ser1070) polyclonal antibody. phospho-PI3 Kinase p110 beta (Ser1070) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, rat, and predicted: chicken, dog, pig, cow, horse, guinea pig background without labeling.

HY-P81162

PIK3CA Antibody PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB; ELISA; IHC-P; IHC-F; ICC; IF	Human, Mouse, Rat(predicted: Chicken, Cow, Rabbit)
PIK3CA Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-PIK3CA polyclonal antibody. PIK3CA Antibody can be used for: WB, ELISA, IHC-P, IHC-F, ICC, IF expriments in human, mouse, rat, and predicted: chicken, cow, rabbit background without labeling.

HY-P81199

phospho-PI3KCA (Tyr317) Antibody PIK3CA(phospho Y317); PI3 kinase p110 subunit alpha; caPI3K; MGC142161; MGC142163; p110 alpha; Phosphatidylinositol 3 kinase catalytic alpha polypeptide; Phosphatidylinositol 3 kinase catalytic 110 KD alpha; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit alpha isoform; Phosphoinositide 3 kinase catalytic alpha polypeptide; PI3 kinase p110 subunit alpha; PI3K; PI3KC A; PIK3C A; PIK3CA; PK3CA; PtdIns 3 kinase p110; PI3-kinase P110α; PI3-kinase p110 subunit alpha; PI 3 kinase catalytic subunit alpha; PK3CA_HUMAN; PI3 kinase P110α.	WB; ELISA; IHC-P; IHC-F; IF	Human, Mouse(predicted: Rat)
phospho-PI3KCA (Tyr317) Antibody is an unconjugated, approximately 117 kDa, rabbit-derived, anti-phospho-PI3KCA (Tyr317) polyclonal antibody. phospho-PI3KCA (Tyr317) Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat background without labeling.

HY-P81872

PI3 Kinase p110 delta Antibody (YA1617) PIK3CD; Phosphatidylinositol 4; 5-bisphosphate 3-kinase catalytic subunit delta isoform; PI3-kinase subunit delta; PI3K-delta; PI3Kdelta; PtdIns-3-kinase subunit delta; Phosphatidylinositol 4; 5-bisphosphate 3-kinase 110 kDa catalytic subunit delta; PtdIns-3-kinase subunit p110-delta; p110delta	WB, ICC/IF	Human, Mouse, Rat

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks